Format

Send to

Choose Destination
Cancer Sci. 2018 Nov;109(11):3383-3392. doi: 10.1111/cas.13799. Epub 2018 Oct 20.

Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.

Author information

1
Health Research Institute, Faculty of ESTeM, University of Canberra, Canberra, ACT, Australia.
2
Department of Medical Oncology, The Canberra Hospital, Canberra, ACT, Australia.
3
QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
4
ANU Medical School, Australian National University, Canberra, ACT, Australia.
5
Department of Anatomical Pathology, ACT Pathology, The Canberra Hospital, Canberra, ACT, Australia.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with poor survival outcomes. Currently, there are no targeted therapies available for TNBCs despite remarkable progress in targeted and immune-directed therapies for other solid organ malignancies. Poly (ADP-ribose) polymerase inhibitors (PARPi) are effective anticancer drugs that produce good initial clinical responses, especially in homologous recombination DNA repair-deficient cancers. However, resistance is the rule rather than the exception, and recurrent tumors tend to have an aggressive phenotype associated with poor survival. Many efforts have been made to overcome PARPi resistance, mostly by targeting genes and effector proteins participating in homologous recombination that are overexpressed during PARPi therapy. Due to many known and unknown compensatory pathways, genes, and effector proteins, overlap and shared resistance are common. Overexpression of programmed cell death-ligand 1 (PD-L1) and cancer stem cell (CSC) sparing are novel PARPi resistance hypotheses. Although adding programmed cell death-1 (PD-1)/PD-L1 inhibitors to PARPi might improve immunogenic cell death and be crucial for durable responses, they are less likely to target the CSC population that drives recurrent tumor growth. Lysine-specific histone demethylase-1A and histone deacetylase inhibitors have shown promising activity against CSCs. Combining epigenetic drugs such as lysine-specific histone demethylase-1A inhibitors or histone deacetylase inhibitors with PARPi/anti-PD-1/PD-L1 is a novel, potentially synergistic strategy for priming tumors and overcoming resistance. Furthermore, such an approach could pave the way for the identification of new upstream epigenetic and genetic signatures.

KEYWORDS:

cancer stem cell; immune checkpoint inhibitor; lysine-specific histone demethylase-1A; poly (ADP-ribose) polymerase inhibitor; triple-negative breast cancer

PMID:
30230653
PMCID:
PMC6215877
DOI:
10.1111/cas.13799
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center